



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/790,730	03/03/2004	Makoto Ozeki	1422-0625P	2621
2292	7590	01/14/2011	EXAMINER	
BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040-0747				CLAYTOR, DEIRDRE RENEE
ART UNIT		PAPER NUMBER		
1627				
NOTIFICATION DATE			DELIVERY MODE	
01/14/2011			ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

Office Action Summary	Application No.	Applicant(s)	
	10/790,730	OZEKI ET AL.	
	Examiner	Art Unit	
	Renee Claytor	1627	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 04 November 2010.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 5,7 and 13 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 5, 7, 13 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date. _____ .	6) <input type="checkbox"/> Other: _____ .

DETAILED ACTION

Response to Arguments

Applicants argue over the 35 USC 103 rejection over Ueda (US Patent 6,831,103) in view of Hamilton (J Neurol Neurosurg Psychiat, 1960, 23, 56). In particular, Applicants argue that the mood disorder in the present invention has symptoms similar to depression which is in contrast to Ueda which relates to suppression of anxiety and not to feelings of guilt or suicide. Applicants also argue that the various symptoms caused due to diminished homeostasis do not have a direct relationship to retardation:psychomotor. Applicants also argue that Ueda discloses a connection between a person with a lack of folate and various diseases, which does not teach a normofolatemic patient.

In response to the above arguments, it is again noted that Ueda et al. teaches that theanine ameliorates symptoms accompanying diminished homeostasis and that diminished homeostasis is a state wherein stably maintaining morphological and physiological condition in normal ranges is altered. This includes changes in nervous system regulation. Therefore, it is considered that diminished homeostasis falls under the broad term of "mood disorder". Symptoms that accompany diminished homeostasis include bad physical condition, anxiety, spiritlessness, faintheartedness, maudliness, psychological lift and autonomic imbalance symptoms which meet the symptoms of retardation:psychomotor. Further, Applicants arguments that Ueda discloses a connection between a person with a lack of folate and various diseases; however, Ueda

makes no mention of folate in the reference. Therefore the argument is not found persuasive.

The arguments are not found persuasive and the rejections are maintained below.

Claim Rejections – 35 U.S.C. § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 5, 7 and 13 rejected under 35 U.S.C. 103(a) as being unpatentable over Ueda et al. (U.S. Patent 6,831,103) in view of Hamilton (J Neurol Neurosurg Psychiat, 1960, 23, 56).

Ueda et al. teaches the administration of a theanine-containing composition that is capable of ameliorating symptoms such as anxiogenic symptoms that include those symptoms due to an unidentified cause and associated with diminished homeostasis (Col. 1, lines 13-22; Col. 4, lines 41-61 and Test Example 3). Further, diminished homeostasis is a disorder that falls under the broad term of mood disorder as claimed and is treated with theanine and further symptoms of diminished homeostasis include spiritlessness, aggressiveness, faintheartedness, maudliness and psychological lift. Further, Ueda et al. teaches that diminished homeostasis is a state wherein stably

maintaining morphological and physiological conditions in normal ranges in altered and this includes changes in nervous system regulation (Col. 3, lines 60 – Col. 4, lines 1-6). Ueda et al. further teach that theanine may be contained in different types of food or beverages (Col. 6, lines 8-67 – Col. 7, lines 1-17). Ueda et al. is silent as to whether the patient is normofolatemic or not. However, absence a showing of criticality that the product shows unexpected results in normofolatemic patients, the invention is deemed obvious over Ueda et al. Ueda et al. does not specify that the symptoms of mood disorder as feelings of guilt, suicide and retardation:psychomotor; however, Ueda et al. generally teaches treating symptoms of mood disorder which would include all of these symptoms. Primarily anxiogenic symptoms are often indicated in feelings of guilt and suicide. Further diminished homeostasis symptoms read on the symptoms of retardation:psychomotor. Accordingly, Ueda et al. teaches treating mood symptoms which render the present invention obvious.

Ueda et al. do not specifically teach that the mood is assessed by the Hamilton scale or all of the different types of mood listed in claims 9-11.

Hamilton teaches a rating scale for measuring symptoms of mental disorder, including the symptoms such as feelings of guilt, suicide, retardation:psychomotor and diminished insight (see whole document).

Accordingly, it would be obvious to a person of ordinary skill in the art at the time of the invention that the Hamilton scale would be an effective assessment of symptoms of mood disorders because of the teachings of Ueda et al. that theanine containing compositions are effective in treating various types of mood, particularly those

associated with anxiety and diminished homeostasis. One would be motivated to use the Hamilton scale because it is a scale commonly used to assess various mood disorders, including depressed states. Therefore, the other factors in the scale would also be measured.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Renee Claytor whose telephone number is (571)272-8394. The examiner can normally be reached on M-F 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Shengjun Wang/
Primary Examiner, Art Unit 1627

Renee Claytor